Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
10908 | 957 | 39.4 | 85% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
547 | 13910 | SCORPION TOXINS//SCORPION VENOM//POTASSIUM CHANNEL |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | RETIGABINE | Author keyword | 160 | 81% | 10% | 97 |
2 | FLUPIRTINE | Author keyword | 115 | 79% | 8% | 73 |
3 | KCNQ | Author keyword | 73 | 61% | 8% | 78 |
4 | M CURRENT | Author keyword | 73 | 53% | 10% | 97 |
5 | BFNC | Author keyword | 65 | 95% | 2% | 21 |
6 | KCNQ2 | Author keyword | 54 | 76% | 4% | 38 |
7 | EZOGABINE | Author keyword | 51 | 91% | 2% | 21 |
8 | LINOPIRDINE | Author keyword | 50 | 77% | 4% | 34 |
9 | KV7 | Author keyword | 46 | 72% | 4% | 36 |
10 | KCNQ CHANNELS | Author keyword | 33 | 75% | 3% | 24 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | RETIGABINE | 160 | 81% | 10% | 97 | Search RETIGABINE | Search RETIGABINE |
2 | FLUPIRTINE | 115 | 79% | 8% | 73 | Search FLUPIRTINE | Search FLUPIRTINE |
3 | KCNQ | 73 | 61% | 8% | 78 | Search KCNQ | Search KCNQ |
4 | M CURRENT | 73 | 53% | 10% | 97 | Search M+CURRENT | Search M+CURRENT |
5 | BFNC | 65 | 95% | 2% | 21 | Search BFNC | Search BFNC |
6 | KCNQ2 | 54 | 76% | 4% | 38 | Search KCNQ2 | Search KCNQ2 |
7 | EZOGABINE | 51 | 91% | 2% | 21 | Search EZOGABINE | Search EZOGABINE |
8 | LINOPIRDINE | 50 | 77% | 4% | 34 | Search LINOPIRDINE | Search LINOPIRDINE |
9 | KV7 | 46 | 72% | 4% | 36 | Search KV7 | Search KV7 |
10 | KCNQ CHANNELS | 33 | 75% | 3% | 24 | Search KCNQ+CHANNELS | Search KCNQ+CHANNELS |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ANTICONVULSANT RETIGABINE | 327 | 88% | 16% | 152 |
2 | D 23129 | 142 | 96% | 5% | 45 |
3 | KV7 CHANNELS | 100 | 90% | 5% | 44 |
4 | DUP 996 | 80 | 90% | 4% | 35 |
5 | KCNQ2 KCNQ3 K CHANNELS | 64 | 86% | 3% | 32 |
6 | KCNQ POTASSIUM CHANNELS | 62 | 73% | 5% | 47 |
7 | KCNQ2 KCNQ3 | 60 | 100% | 2% | 20 |
8 | RETIGABINE | 58 | 73% | 5% | 45 |
9 | LINOPIRDINE DUP 996 | 56 | 80% | 4% | 35 |
10 | KCNQ2 | 42 | 61% | 5% | 44 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Neural KCNQ (Kv7) channels | 2009 | 183 | 75 | 77% |
The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy | 2012 | 46 | 57 | 81% |
Flupirtine, a re-discovered drug, revisited | 2013 | 12 | 61 | 74% |
Molecular pharmacology and therapeutic potential of neuronal Kv7-modulating drugs | 2008 | 54 | 72 | 89% |
Pathways modulating neural KCNQ/M (Kv7) potassium channels | 2005 | 288 | 112 | 47% |
Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data | 2012 | 13 | 48 | 85% |
Driving With No Brakes: Molecular Pathophysiology of Kv7 Potassium Channels | 2011 | 30 | 110 | 55% |
One man's side effect is another man's therapeutic opportunity: targeting Kv7 channels in smooth muscle disorders | 2013 | 6 | 74 | 84% |
Flupirtine in Pain Management Pharmacological Properties and Clinical Use | 2010 | 25 | 35 | 89% |
Kv7 Channels as Targets for the Treatment of Pain | 2009 | 25 | 91 | 89% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | NEW LEADS BIOL | 8 | 100% | 0.5% | 5 |
2 | ASTA MED GRP | 6 | 58% | 0.7% | 7 |
3 | ABT MED DEUT LAND | 3 | 100% | 0.3% | 3 |
4 | PHARMACOL CELL PHYSIOL GRP | 2 | 44% | 0.4% | 4 |
5 | CNRSUMR 6150 | 2 | 67% | 0.2% | 2 |
6 | NEUROL UNIT S | 2 | 67% | 0.2% | 2 |
7 | LEHRSTUHL BIOCHEM REZEPTORBIOCHEM 1 | 1 | 100% | 0.2% | 2 |
8 | SECT EARLY TARGET PHARMACOL PHYSIOL | 1 | 100% | 0.2% | 2 |
9 | WELLCOME MOL PHARMACOL | 1 | 14% | 0.8% | 8 |
10 | ABT NEUROL WERPUNKT EPILEPTOL | 1 | 24% | 0.4% | 4 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000133067 | DRAVET SYNDROME//SCN1A//GEFS |
2 | 0.0000132724 | SYMPATHETIC GANGLION CELLS//M CURRENT//NICOTINIC SYNAPSES |
3 | 0.0000121572 | LACOSAMIDE//ESLICARBAZEPINE ACETATE//PERAMPANEL |
4 | 0.0000084366 | APAMIN//SK CHANNELS//SMALL CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL |
5 | 0.0000072529 | LONG QT SYNDROME//KCNQ1//SHORT QT SYNDROME |
6 | 0.0000061182 | KCSA//EPISODIC ATAXIA TYPE 1//MOL NEUROBIOL BIOPHYS |
7 | 0.0000061046 | PAROXYSMAL KINESIGENIC DYSKINESIA//PRRT2//PAROXYSMAL KINESIGENIC CHOREOATHETOSIS |
8 | 0.0000058194 | NODE OF RANVIER//AXON INITIAL SEGMENT//PARANODE |
9 | 0.0000049852 | HERG//HUMAN ETHER A GO GO RELATED GENE//HERG CHANNEL |
10 | 0.0000045841 | K 2P CHANNEL//K 2P CHANNELS//TREK 1 |